Quantum BioPharma

02/02/2026

At Quantum BioPharma, we’re advancing science with the goal of improving outcomes for people living with multiple sclerosis.

Learn more about Lucid-MS:
https://www.quantumbiopharma.com/lucid-ms $QNTM

01/13/2026

Alleged stock spoofing takes center stage as Quantum BioPharma Co-Founder Anthony Durkacz speaks with host Tracy Hughes

David vs 13 Goliaths.’ Anthony Durkacz explains why Quantum BioPharma ($QNTM) launched a $700M class action over alleged stock spoofing by major banks, saying everyday investors were harmed, market integrity was undermined, and that while fighting manipulation, the company continues advancing Lucid-MS toward Phase 2 to help MS patients

youtu.be/fk_R0cpg7aY?si…

$QNTM

From the outset of his conversation with InvestorNews.com host Tracy Hughes, Anthony Durkacz pulled no punches: the fight his company has launched against al...

01/05/2026

Learn more about Lucid-MS by visiting our website https://www.quantumbiopharma.com/lucid-ms

$QNTM

12/31/2025

Happy New Year from all of us at Quantum BioPharma.

Thank you to our shareholders, partners, and supporters for being part of our journey.

Wishing everyone a healthy and successful year ahead.

$QNTM

12/24/2025

Happy Holidays from Quantum BioPharma.
We extend our best wishes to our shareholders, stakeholders, and partners, and wish everyone a healthy season ahead.

12/23/2025

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 Trial

https://www.globenewswire.com/news-release/2025/12/23/3209828/0/en/Quantum-Biopharma-Announces-Completion-of-Dosing-in-180-Day-Repeated-Dose-Oral-Toxicity-and-Toxicokinetic-Studies-for-Lucid-21-302-Lucid-MS.html

$QNTM

12/19/2025

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

https://globenewswire.com/news-release/2025/12/19/3208756/0/en/World-Renowned-Law-Firm-Grant-Eisenhofer-Files-Class-Action-Lawsuit-Against-Canadian-Banks-CIBC-and-RBC-Alleging-Illegal-Stock-Market-Manipulation-of-Quantum-BioPharma-Shares.html

$QNTM

12/10/2025

Most people think MS is just the immune system attacking myelin — but one of the earliest changes happens insidethe myelin itself.
A healthy myelin sheath relies on Myelin Basic Protein (MBP) to stay compact and stable.

But in MS, MBP can undergo citrullination — a chemical modification that changes the protein’s charge and weakens its structure.
When MBP becomes citrullinated, the myelin layers loosen, electrical conduction slows, and the axon becomes far more vulnerable to demyelination.

➡️ MBP citrullination → myelin instability → demyelination → neurological decline.
This upstream biology is becoming an important area of research in understanding how MS progresses over time.

Quantum BioPharma is focused on advancing science in this space and exploring how targeted small molecules may support healthier myelin structure and function.

Understanding citrullination is key. Understanding demyelination is essential. Advancing research matters.
$QNTM

12/01/2025

Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC

https://www.globenewswire.com/news-release/2025/12/01/3196861/0/en/Investigative-News-Program-W5-Airs-Final-Segment-on-USD-700-Million-Stock-Market-Manipulation-Lawsuit-of-Quantum-Biopharma-Involving-CIBC-and-RBC.html

$QNTM

11/28/2025

Breakthroughs in MS don’t happen by accident — they happen when someone finally looks at the biology differently.

Most treatments in MS still revolve around the autoimmune narrative. But the science is shifting.
Demyelination has a biochemical signature: citrullination.

When myelin proteins become over-citrullinated, the sheath weakens, repair fails, and disease progression accelerates.

That’s why Lucid-MS stands out. It’s a new chemical entity built around the neurodegenerative side of MS — the part traditional drugs don’t touch.

Strong research deserves a fair environment to advance.

MS patients need real innovation. And the biology behind this one is worth paying attention to.

Learn More at https://quantumbiopharma.com/lucid-ms

$QNTM

11/27/2025

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

Thank you CTV News & Reporter Jon Woodward for the extensive coverage on these topics.

https://www.globenewswire.com/news-release/2025/11/27/3195939/0/en/Award-winning-Investigative-News-Program-W5-Airs-Part-2-of-3-part-Television-Series-on-Alleged-Stock-Market-Manipulation-of-Quantum-Biopharma-Involving-Two-of-Canada-s-Largest-Bank.html

$QNTM

11/27/2025

Thanks CTV News & W5's Investigative Journalism for taking the time to cover Quantum BioPharma’s story and for digging deeply into the alleged market-manipulation issues. $QNTM

W5's Jon Woodward () investigates the rise of stock spoofing and the push within Canada for steeper penalties to take the profit out of the rapidly evolving tactic.

$QNTM